A chimeric antigen receptor T cell, its preparation method and application

By knocking out the TRAC and CD95 genes in CAR-T cells, expressing anti-PD-1 antibodies and combining them with HLA-E expression or knocking out HLA-A and HLA-B, allogeneic universal CAR-T cells are prepared, solving the problems of poor killing effect and insufficient safety in existing technologies, and achieving more efficient and safer tumor treatment.

CN123107932APending Publication Date: 2026-11-17CELLS & GENES BIOTECH (SHANGHAI) CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202510621147.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-05-14
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing universal CAR-T cells have problems with poor killing effect and insufficient safety when treating hematologic malignancies, especially when used in allogeneic applications, they are prone to causing host immune rejection and NK cell killing.

Method used

By knocking out the TRAC and CD95 genes of T cells, expressing chimeric antigen receptors (CARs) and secreting anti-PD-1 antibodies, and combining HLA-E expression or knocking out HLA-A and HLA-B, allogeneic universal CAR-T cells can be prepared, enhancing tumor targeting and reducing immune rejection.

Benefits of technology

It improves the tumor-killing effect of CAR-T cells, reduces host immune rejection and NK cell killing rate, reduces the systemic toxicity side effects of anti-PD-1 antibodies, and achieves more efficient and safer tumor treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005402538400000171
    Figure BDA0005402538400000171
  • Figure BDA0005402538400000181
    Figure BDA0005402538400000181
  • Figure BDA0005402538400000182
    Figure BDA0005402538400000182
Patent Text Reader

Abstract

This invention relates to a chimeric antigen receptor T cell, its preparation method, and its applications. Specifically, this invention provides a CAR-T cell co-expressing an anti-PD-1 antibody; it also provides a universal allogeneic UCAR-T cell, which reduces the host's rejection response to allogeneic cells by knocking out a combination of immune rejection-related genes, and simultaneously reduces the killing rate of UCAR-T cells by the host's NK cells; this invention further provides a method for preparing UCAR-T cells using non-viral plasmid electroporation, allowing for simultaneous gene knockout and knock-in in a single electroporation. The CAR-T cells of this invention exhibit excellent tumor-suppressive effects and have broad application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biomedicine, specifically to a chimeric antigen receptor T cell, its preparation method, and its application. Background Technology

[0002] Immunotherapy, particularly adoptive T-cell therapy, has demonstrated strong efficacy and promising prospects in clinical trials for treating hematologic malignancies. T cells can be genetically modified to express chimeric antigen receptors (CARs), which include an antigen recognition portion and a T-cell activation region. CARs utilize the antigen-binding properties of monoclonal antibodies to redirect the specificity and reactivity of T cells and target their targets in a non-MHC-restricted manner. This non-MHC-restricted antigen recognition allows CAR-expressing T cells to recognize antigens without antigen processing, thus avoiding a major mechanism of tumor escape. Furthermore, CARs do not dimerize with the α- and β-chains of endogenous TCRs.

[0003] Universal CAR-T cells are an important alternative resource of autologous T cells in T-cell immunotherapy. Knocking out endogenous TRAC and B2M genes in allogeneic T cells helps prevent graft-versus-host disease and host immune rejection, respectively. These gene-edited cells from allogeneic donors offer cellular immunotherapy opportunities for patients who cannot obtain sufficient autologous T cells. However, current research on universal CAR-T cells still has many shortcomings.

[0004] Therefore, there is an urgent need in this field to develop new universal CAR-T cell products with good killing effect and high safety. Summary of the Invention

[0005] The purpose of this invention is to provide a chimeric antigen receptor T cell, its preparation method, and its application.

[0006] In a first aspect of the invention, an engineered T cell is provided, the engineered T cell expressing a chimeric antigen receptor (CAR) and the engineered T cell secreting an anti-PD-1 antibody, the anti-PD-1 antibody having the following combination of complementarity-determining regions (CDRs):

[0007] CDR1: PCTMA (SEQ ID NO:1)

[0008] CDR2: SIYTTTGITYYTDSVQG(SEQ ID NO:2), or

[0009] SIYTTTGITYYADSVKG(SEQ ID NO:34);

[0010] CDR3: ALTEIGRYRLYARQYDF (SEQ ID NO: 3).

[0011] In another preferred embodiment, the anti-PD-1 antibody has the following combination of complementarity-determining regions (CDRs):

[0012] CDR1: PCTMA (SEQ ID NO:1)

[0013] CDR2:SIYTTTGITYYTDSVQG(SEQ ID NO:2);

[0014] CDR3:ALTEIGRYRLYARQYDF(SEQ ID NO:3);

[0015] or

[0016] CDR1: PCTMA (SEQ ID NO:1)

[0017] CDR2: SIYTTTGITYYADSVKG (SEQ ID NO:34);

[0018] CDR3: ALTEIGRYRLYARQYDF (SEQ ID NO: 3).

[0019] In another preferred embodiment, the anti-PD-1 antibody has a CDR region of a heavy chain variable region sequence as shown in any one of SEQ ID NO:4-6.

[0020] In another preferred embodiment, the anti-PD-1 antibody is a nanobody (VHH).

[0021] In another preferred embodiment, the sequence of the anti-PD-1 antibody is selected from the group consisting of:

[0022] (a) A sequence as shown in any one of SEQ ID NO:4-6; or

[0023] (b) A sequence that has at least 90% sequence identity with any of the sequences shown in SEQ ID NO:4-6.

[0024] In another preferred embodiment, the engineered T cells further express exogenous proteins selected from the group consisting of cytokines, inhibitory signal blocking proteins, chimeric antigen receptors (CARs), or combinations thereof.

[0025] In another preferred embodiment, the cytokines include IL-15, IL-21, IL-2, IL-4, IL-7, IL-18, or combinations thereof.

[0026] In another preferred embodiment, the inhibitory signal blocking protein includes: an anti-TIGIT antibody, a dominant mutant TGF-β receptor II (dnTGFβRII), CD73, or a combination thereof.

[0027] In another preferred embodiment, the anti-TIGIT antibody is a single-chain antibody, and preferably, the sequence of the anti-TIGIT antibody is shown in SEQ ID NO:31.

[0028] In another preferred embodiment, the sequence of the dnTGFβRII is as shown in SEQ ID NO:27.

[0029] In another preferred embodiment, the T cells include autologous or allogeneic T cells.

[0030] In another preferred embodiment, the engineered T cells are universal engineered T cells.

[0031] In another preferred embodiment, the CD95 gene of the universal engineered T cells is knocked out or silenced.

[0032] In another preferred embodiment, the TRAC gene of the universal engineered T cell is knocked out or silenced.

[0033] In another preferred embodiment, the coding sequences of the CAR, anti-PD-1 antibody, and optional exogenous protein are integrated into the TRAC site of T cells, thereby knocking out or silencing the TRAC gene in universal engineered T cells.

[0034] In another preferred embodiment, the universal engineered T cell further comprises features selected from the group consisting of:

[0035] (1) Knock out B2M and CIITA and express exogenous HLA-E;

[0036] (2) Knock out HLA-A, HLA-B and CIITA.

[0037] In another preferred embodiment, the structure of the chimeric antigen receptor is shown in Formula I:

[0038] L-ECD-H-TM-C-CD3ζ(I)

[0039] In the formula,

[0040] Each "-" independently represents a linking peptide or peptide bond;

[0041] L represents the absence of a signal peptide sequence;

[0042] ECD is the extracellular binding domain sequence that binds to the antigen;

[0043] H is an optional hinge area;

[0044] TM stands for transmembrane region;

[0045] C represents a non- or co-stimulatory signaling molecule;

[0046] CD3ζ is a cytoplasmic signal transduction sequence derived from CD3ζ.

[0047] In another preferred embodiment, L is a signal peptide of a protein selected from the group consisting of CD8, GM-CSF, CD4, CD137, or a combination thereof.

[0048] In another preferred embodiment, the ECD is a scFv or VHH targeting the antigen.

[0049] In another preferred embodiment, the ECD-targeted antigen is selected from the group consisting of GPC3, BCMA, CD19, CD123, CD22, CD30, CD171, CLL-1, CD33, EGFRvIII, GD2, GD3, FLT3, CEA, EPCAM, B7H3, mesothelin, MUC1, EGFR, CLDN6, GPRC5D, CDH17, or combinations thereof.

[0050] In another preferred embodiment, the ECD is a scFv or VHH targeting a target selected from the group consisting of GPC3, BCMA, and CD19.

[0051] In another preferred embodiment, the sequence of the ECD is as shown in any one of SEQ ID NO:19-21.

[0052] In another preferred embodiment, H is a hinge region of a protein selected from the group consisting of CD8, CD28, CD137, IgG, or combinations thereof.

[0053] In another preferred embodiment, H is the hinge region of the CD8a protein.

[0054] In another preferred embodiment, the TM is a transmembrane region of a protein selected from the group consisting of: CD28, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, or a combination thereof.

[0055] In another preferred embodiment, the TM is the transmembrane region of the CD8a protein.

[0056] In another preferred embodiment, C is a co-stimulatory signaling molecule selected from the group consisting of: 4-1BB (CD137), CD28, OX40, CD2, CD7, CD27, CD30, CD40, CD70, CD134, PD1, Dap10, CDS, ICAM-1, LFA-1 (CD11a / CD18), ICOS (CD278), NKG2D, GITR, TLR2, or combinations thereof.

[0057] In another preferred embodiment, C is a co-stimulatory signaling molecule of the 4-1BB protein.

[0058] In another preferred embodiment, the co-stimulatory signaling molecule and the cytoplasmic signaling sequence derived from CD3ζ together constitute the intracellular region of the CAR.

[0059] In another preferred embodiment, the sequences of the hinge region, transmembrane region and intracellular region of the CAR are as shown in SEQ ID NO:22.

[0060] In another preferred embodiment, the CAR, anti-PD-1 antibody, and optional exogenous protein are expressed by the same vector or different vectors, preferably by the same vector.

[0061] In another preferred embodiment, the tumor is selected from the group consisting of hematologic malignancies, solid tumors, or combinations thereof.

[0062] In another preferred embodiment, the hematologic malignancy is selected from the group consisting of multiple myeloma (MM), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), or combinations thereof.

[0063] In another preferred embodiment, the solid tumor is selected from the group consisting of: liver cancer, stomach cancer, kidney tumor, lung cancer, small intestine cancer, bone cancer, prostate cancer, colorectal cancer, breast cancer, colon cancer, cervical cancer, ovarian cancer, lymphoma, nasopharyngeal carcinoma, adrenal tumor, bladder tumor, glioma, endometrial cancer, testicular cancer, colorectal cancer, urinary tract tumor, thyroid cancer, or combinations thereof.

[0064] In another preferred embodiment, the solid tumor is liver cancer.

[0065] In a second aspect of the invention, a universal allogeneic CAR-T cell is provided, wherein the TRAC gene and / or CD95 gene of the universal allogeneic CAR-T cell are knocked out or silenced, and the universal allogeneic CAR-T cell has characteristics selected from the group consisting of:

[0066] (1) Knock out B2M and CIITA to express HLA-E; or

[0067] (2) Knock out HLA-A, HLA-B and CIITA.

[0068] In another preferred embodiment, the allogeneic universal CAR-T cells secrete an anti-PD-1 antibody, which is as described above.

[0069] In another preferred embodiment, the CAR expressed by the allogeneic universal CAR-T cells is as described above.

[0070] In another preferred embodiment, the coding sequences of the CAR and the anti-PD-1 antibody are integrated into the TRAC site of the T cell, thereby knocking out or silencing the TRAC gene of the universal engineered T cell.

[0071] In another preferred embodiment, "gene knocked out or silenced" means that the gene is not expressed or is expressed at low levels.

[0072] In another preferred embodiment, "low expression" means that the gene expression level G1 of the CAR-T cell is G1 / G0 ≤ 0.5 compared with the gene expression level G0 of the normal T cell, preferably G1 / G0 ≤ 0.3, more preferably ≤ 0.2, more preferably ≤ 0.1, and most preferably 0.

[0073] In another preferred embodiment, the HLA-E is expressed as a single-chain trimer (HLA-E SCT), the sequence of which is shown in SEQ ID NO:30.

[0074] In a third aspect of the invention, a polynucleotide is provided, the polynucleotide comprising a coding sequence for a secretory anti-PD-1 antibody, and the polynucleotide further comprising a coding sequence for one or more proteins selected from the group consisting of:

[0075] (1) Chimeric antigen receptor CAR;

[0076] (2) Cytokines;

[0077] (3) Inhibitory signal blocking proteins;

[0078] (4) HLA-E;

[0079] The anti-PD-1 antibody has the following combination of complementarity-determining regions (CDRs):

[0080] CDR1: PCTMA (SEQ ID NO:1)

[0081] CDR2: SIYTTTGITYYTDSVQG(SEQ ID NO:2), or

[0082] SIYTTTGITYYADSVKG(SEQ ID NO:34);

[0083] CDR3: ALTEIGRYRLYARQYDF (SEQ ID NO: 3).

[0084] In another preferred embodiment, the cytokines include IL-15, IL-21, IL-2, IL-4, IL-7, IL-18, or combinations thereof.

[0085] In another preferred embodiment, the inhibitory signal blocking protein includes: an anti-TIGIT antibody, a dominant mutant TGF-β receptor II (dnTGFβRII), CD73, or a combination thereof.

[0086] In another preferred embodiment, the HLA-E is expressed as a single-chain trimer (HLA-E SCT), the sequence of which is shown in SEQ ID NO:30.

[0087] In another preferred embodiment, the polynucleotide is DNA or RNA, preferably DNA.

[0088] In another preferred embodiment, the coding sequences of the various proteins are linked by self-cleaving coding sequences of 2A peptides, including P2A, E2A, T2A, F2A, etc.

[0089] In another preferred embodiment, the polynucleotide contains left and right homologous arm sequences targeting the TRAC gene.

[0090] In a fourth aspect of the invention, a carrier is provided, the carrier containing the polynucleotide as described in the third aspect of the invention.

[0091] In another preferred embodiment, the vector is selected from the group consisting of plasmids, viral vectors, transposons, or combinations thereof.

[0092] In another preferred embodiment, the viral vector is selected from the group consisting of lentiviral vectors, adenovirus vectors, adeno-associated virus vectors, or combinations thereof.

[0093] In another preferred embodiment, the vector is a plasmid vector.

[0094] In a fifth aspect of the invention, a pharmaceutical composition is provided, the pharmaceutical composition comprising:

[0095] (1) Active ingredients selected from the group consisting of engineered T cells as described in the first aspect of the present invention, or allogeneic universal CAR-T cells as described in the second aspect of the present invention; and

[0096] (2) Pharmaceutically acceptable carrier.

[0097] In another preferred embodiment, the pharmaceutical composition is a liquid formulation.

[0098] In another preferred embodiment, the pharmaceutical composition is an injection or a lyophilized preparation.

[0099] In another preferred embodiment, the pharmaceutical composition is formulated for intravenous administration.

[0100] In another preferred embodiment, the concentration of engineered T cells in the pharmaceutical composition is 1 × 10⁻⁶. 3 -5×108 Cells / ml, preferably 1×10⁻⁶ 4 -1×10 8 cells / ml; or

[0101] The concentration of allogeneic universal CAR-T cells in the pharmaceutical composition is 1×10⁻⁶. 3 -5×10 8 Cells / ml, preferably 1×10⁻⁶ 4 -1×10 8 Cells / ml

[0102] In another preferred embodiment, the pharmaceutical composition comprises 0.01 to 99.99% engineered T cells as described in the first aspect of the invention, or allogeneic universal CAR-T cells as described in the second aspect of the invention; and 0.01 to 99.99% pharmaceutically acceptable carrier, the percentage being a percentage by mass of the pharmaceutical composition.

[0103] In another preferred embodiment, the pharmaceutical composition includes buffers such as neutral buffered saline, sulfate buffered saline, etc.; carbohydrates such as glucose, mannose, sucrose or dextran, mannitol; proteins; peptides or amino acids such as glycine; antioxidants; chelating agents such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide); and preservatives.

[0104] In another preferred embodiment, when the pharmaceutical composition is administered, the effector-to-target ratio of engineered T cells or allogeneic universal CAR-T cells to tumor cells is (0.1-20):1, such as (10-20):1, (1-20):1, (1-10):1, (1-5):1, 3:1, (0.1-1):1.

[0105] In a sixth aspect of the invention, a method for preparing engineered T cells as described in the first aspect of the invention is provided, the method comprising the steps of: providing T cells to be modified, and transducing the T cells with a polynucleotide as described in the third aspect of the invention or a vector as described in the fourth aspect of the invention, thereby obtaining the engineered T cells.

[0106] In another preferred embodiment, the method further includes a step of testing the function and effectiveness of the obtained engineered immune cells.

[0107] In a seventh aspect of the invention, a method for preparing allogeneic universal CAR-T cells as described in the second aspect of the invention is provided, the method comprising providing T cells to be modified and performing the following operations on the T cells:

[0108] (a) Knock out the immune rejection-related gene combination in the T cells;

[0109] (b) Transfecting the exogenous vector expressing CAR into the T cells;

[0110] The combination of immune rejection-related genes is as follows:

[0111] (1) TRAC, B2M, CIITA, and CD95; or

[0112] (2)TRAC, HLA-A, HLA-B, CIITA and CD95.

[0113] In another preferred embodiment, steps (a) and (b) may be performed sequentially or simultaneously.

[0114] In another preferred embodiment, the knockout is performed using a CRISPR / Cas9, ZFN, or TALEN system, preferably a CRISPR / Cas9 system.

[0115] In another preferred embodiment, the knockout method is as follows: sgRNA targeting a combination of immune rejection-related genes is mixed with Cas9 protein and then delivered into the T cells.

[0116] In another preferred embodiment, the sequence of the sgRNA is as follows:

[0117] TRAC:TCAGGGTTCTGGATATCTGT(SEQ ID NO:7);

[0118] HLA-A: GGACCTGCGCTCTTGGACCG (SEQ ID NO: 8);

[0119] HLA-B:GCTGTCGAACCTCACGAACT(SEQ ID NO:9);

[0120] CIITA:TCAACTGCGACCAGTTCAGC(SEQ ID NO:10);

[0121] B2M: CGCGAGCACAGCTAAGGCCA (SEQ ID NO: 11);

[0122] CD95: GAGGGTCCAGATGCCCAGCA (SEQ ID NO: 12).

[0123] In another preferred embodiment, the method specifically includes:

[0124] (S1) A mixture is provided, the mixture comprising: an exogenous vector expressing CAR, sgRNA and Cas9 protein knocked out a combination of immune rejection-related genes; wherein the exogenous vector is a plasmid and the plasmid contains a homologous arm targeting the TRAC gene;

[0125] (S2) The mixture from step (S1) is delivered into T cells via electroporation.

[0126] In an eighth aspect of the invention, a kit for preparing CAR-T cells is provided, the kit comprising a container, and the following contents located within the container:

[0127] (1) Knock-in reagent, wherein the knock-in reagent comprises an exogenous vector for expressing CAR;

[0128] (2) Knockout reagents are used to knock out or silence combinations of immune rejection-related genes;

[0129] The combination of immune rejection-related genes is as follows:

[0130] (1) TRAC, B2M, CIITA, and CD95; or

[0131] (2)TRAC, HLA-A, HLA-B, CIITA and CD95.

[0132] In another preferred embodiment, the exogenous vector expressing CAR further comprises an anti-PD-1 antibody and, optionally, the coding sequence of an exogenous protein.

[0133] In another preferred embodiment, the definitions of CAR, anti-PD-1 antibody, exogenous protein, and immune rejection-related gene are as described above.

[0134] In another preferred embodiment, the reagent is suitable for delivery to T cells via electroporation.

[0135] In another preferred embodiment, the knockout is performed using a CRISPR / Cas9, ZFN, or TALEN system, preferably a CRISPR / Cas9 system.

[0136] In another preferred embodiment, the knockout reagent comprises: sgRNA and Cas9 protein; the sequence of the sgRNA is selected from the group consisting of:

[0137] TRAC:TCAGGGTTCTGGATATCTGT(SEQ ID NO:7);

[0138] HLA-A: GGACCTGCGCTCTTGGACCG (SEQ ID NO: 8);

[0139] HLA-B:GCTGTCGAACCTCACGAACT(SEQ ID NO:9);

[0140] CIITA:TCAACTGCGACCAGTTCAGC(SEQ ID NO:10);

[0141] B2M: CGCGAGCACAGCTAAGGCCA (SEQ ID NO: 11);

[0142] CD95: GAGGGTCCAGATGCCCAGCA (SEQ ID NO: 12).

[0143] In a ninth aspect of the invention, a method for treating tumors or cancer is provided, comprising administering to a subject requiring treatment an effective amount of engineered T cells as described in the first aspect of the invention, allogeneic universal CAR-T cells as described in the second aspect of the invention, or a pharmaceutical composition as described in the fifth aspect of the invention.

[0144] In another preferred embodiment, the tumor is a solid tumor or a hematologic tumor.

[0145] In another preferred embodiment, the tumor is a tumor that highly expresses antigens selected from the group consisting of: GPC3, BCMA, CD19, CD123, CD22, CD30, CD171, CLL-1, CD33, EGFRvIII, GD2, GD3, FLT3, CEA, EPCAM, B7H3, mesothelin, MUC1, EGFR, CLDN6, GPRC5D, CDH17, or combinations thereof.

[0146] In another preferred embodiment, the tumor is a tumor that highly expresses antigens selected from the group consisting of GPC3, BCMA, and CD19.

[0147] In another preferred embodiment, the hematologic malignancy is selected from the group consisting of multiple myeloma (MM), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), or combinations thereof.

[0148] In another preferred embodiment, the solid tumor is selected from the group consisting of: liver cancer, stomach cancer, kidney tumor, lung cancer, small intestine cancer, bone cancer, prostate cancer, colorectal cancer, breast cancer, colon cancer, cervical cancer, ovarian cancer, lymphoma, nasopharyngeal carcinoma, adrenal tumor, bladder tumor, glioma, endometrial cancer, testicular cancer, colorectal cancer, urinary tract tumor, thyroid cancer, or combinations thereof.

[0149] In another preferred embodiment, the solid tumor is liver cancer.

[0150] In another preferred embodiment, the object is a human or a non-human mammal.

[0151] It should be understood that, within the scope of this invention, the above-described technical features of this invention and the technical features specifically described below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be described in detail here. Attached Figure Description

[0152] Figure 1 The study showed that PD-1 knockout did not significantly enhance CAR-T activation and amplification in vitro for non-viral CAR-T activation.

[0153] Figure 2 This demonstrates the amplification of target cells in response to CAR-T stimulation at a low target-to-E ratio of 1:30.

[0154] Figure 3 The effects of injections of CG-102-12E and CG-102-12E1 on a mouse model of liver cancer are shown. A represents the change in mouse body weight, and B represents the change in subcutaneous tumor volume.

[0155] Figure 4 The cell viability (A), CAR expression rate (B), and total cell count (C) of the five types of CAR-T cells prepared are shown.

[0156] Figure 5 The killing levels of NK cells against five types of UCAR-T cells (A) and cell phenotypes (B) are shown.

[0157] Figure 6 The effects of CG-101-3-55-ABII95 injection on a mouse model of lymphoma are shown. A represents the change in mouse body weight, and B represents the change in subcutaneous tumor volume.

[0158] Figure 7 The effects of CG-102-12B3 injection on a mouse model of liver cancer are shown. A represents the change in mouse body weight, and B represents the change in subcutaneous tumor volume.

[0159] Figure 8 The effects of injections of CG-105-12TB5, CG-105-12TB5-95, and CG-105-12TB5-ABII95 on a mouse model of multiple myeloma are shown. A represents the change in mouse body weight, and B represents the change in subcutaneous tumor volume.

[0160] Figure 9 The activation level (A), pre-injection phenotype (B), and phenotype 34 days after injection (C) of CG-105-12EB-I / II / 95 are shown.

[0161] Figure 10The effects of injections of CG-105-12EB-I / II and CG-105-12EB-I / II / 95 on a mouse model of multiple myeloma are shown. A represents the change in mouse body weight, and B represents the change in subcutaneous tumor volume.

[0162] Figure 11 The effects of CG-105-12EB25-I / II / 95 injection on a mouse model of multiple myeloma are shown. A represents the change in mouse body weight, and B represents the change in subcutaneous tumor volume.

[0163] Figure 12 The results of phenotypic analysis are shown before (A) and 34 days after injection of CG-105-12EB25-I / II / 95.

[0164] Figure 13 The effects of injections of CG-102-12C18B, CG-102-12C18B-95, and CG-102-12C18B-ABII95 on a mouse model of liver cancer are shown. A represents the change in mouse body weight, and B represents the change in subcutaneous tumor volume.

[0165] Figure 14 The results of tumor fluorescence detection in mice 31 days after injection of CG-102-12C18B, CG-102-12C18B-95, and CG-102-12C18B-ABII95 are shown. Detailed Implementation

[0166] Through extensive and in-depth research, the inventors have provided a CAR-T cell co-expressing an anti-PD-1 antibody. This enhances the efficacy of CAR-T therapy for tumors by combining it with the anti-PD-1 antibody, reduces CAR-T cell depletion, and minimizes the potential toxic side effects of systemic injection of the anti-PD-1 antibody. The invention also provides a universal allogeneic UCAR-T cell, which reduces the host's rejection response to allogeneic cells by knocking out a combination of immune rejection-related genes, while also reducing the killing rate of UCAR-T cells by the host's NK cells. Furthermore, the invention provides a method for preparing UCAR-T cells using non-viral plasmid electroporation, allowing for simultaneous gene knockout and knock-in in a single electroporation process, reducing the complexity of preparation and potential damage to T cells. The CAR-T or UCAR-T cells of this invention can be used to treat various cancers. This invention was completed based on these findings.

[0167] definition

[0168] To facilitate a clearer understanding of this disclosure, certain terms are first defined. As used herein, unless otherwise expressly specified herein, each of the following terms shall have the meaning given below.

[0169] The term “about” can refer to a value or composition within an acceptable range of error for a particular value or composition as determined by a person skilled in the art, which will depend in part on how the value or composition is measured or determined.

[0170] The term “administration” means the physical introduction of the product of the present invention into a subject using any of the various methods and delivery systems known to those skilled in the art, including intravenous, intratumoral, intramuscular, subcutaneous, intraperitoneal, spinal, or other parenteral routes of administration, such as by injection or infusion.

[0171] The terms "nanobody" and "single-domain antibody" are used interchangeably, referring to an antibody consisting of only one heavy chain variable region (VHH). It is the smallest antigen-binding fragment with complete function. Typically, antibodies that are naturally missing the light chain and the heavy chain constant region 1 (CH1) are first obtained, and then the variable region of the antibody heavy chain is cloned to construct a nanobody / single-domain antibody consisting of only one heavy chain variable region (VHH).

[0172] CAR-T cells co-expressing anti-PD-1 antibody

[0173] PD-1 (Programmed Cell Death Protein 1) is an important immune checkpoint molecule, primarily expressed on the surface of activated T cells, B cells, and myeloid cells. Its function mainly involves regulating the intensity of T cell immune responses by binding to its ligands PD-L1 or PD-L2, preventing tissue damage caused by excessive immune activation in a normal organism. However, in tumor environments, tumor cells overexpress PD-L1, utilizing this pathway to suppress T cell function, thereby evading immune attack and achieving tumor immune escape.

[0174] During tumor treatment, CAR-T cells are upregulated by PD-1 due to long-term stimulation by tumor antigens on target cells in the body. In addition, molecules such as PD-L1, which are highly expressed in the tumor microenvironment of solid tumors, inhibit CAR-T cells through the PD-1 pathway and other means, leading to CAR-T cell dysfunction.

[0175] Based on this, the present invention provides CAR-T cells co-expressing an anti-PD-1 antibody, wherein the anti-PD-1 antibody has the following combination of complementarity-determining regions (CDRs) (based on the Kabat numbering scheme):

[0176] CDR1: PCTMA (SEQ ID NO:1)

[0177] CDR2:SIYTTTGITYYTDSVQG(SEQ ID NO:2);

[0178] CDR3:ALTEIGRYRLYARQYDF(SEQ ID NO:3);

[0179] or

[0180] CDR1: PCTMA (SEQ ID NO:1)

[0181] CDR2: SIYTTTGITYYADSVKG (SEQ ID NO:34);

[0182] CDR3: ALTEIGRYRLYARQYDF (SEQ ID NO: 3).

[0183] The anti-PD-1 antibody of the present invention is preferably a nanobody (VHH). Nanobodies have the advantage of small molecular weight, which can reduce the volume of the delivery carrier. Preferably, the sequence of the anti-PD-1 antibody is shown in any one of SEQ ID NO:4-6.

[0184] The CAR of the present invention can contain any type of antigen-binding domain that targets tumor antigens.

[0185] The chimeric antigen receptor (CAR) of this invention comprises an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain includes a target-specific binding element (also referred to as an antigen-binding domain). The intracellular domain includes a co-stimulatory signaling region and a ζ-chain portion. The co-stimulatory signaling region refers to a portion of the intracellular domain containing a co-stimulatory molecule. The co-stimulatory molecule is a cell surface molecule required for an effective lymphocyte response to an antigen, rather than an antigen receptor or its ligands.

[0186] In a preferred embodiment of the present invention, the extracellular domain of the CAR provided by the present invention includes an antigen-binding domain that targets various antigens. When the CAR of the present invention is expressed in T cells, it can perform antigen recognition based on antigen-binding specificity.

[0187] As used herein, "antigen-binding domain" and "single-chain antibody fragment" refer to Fab fragments, Fab' fragments, F(ab')2 fragments, or single Fv fragments with antigen-binding activity. Fv antibodies contain variable regions of the antibody heavy chain and light chain, but no constant region, and are the smallest antibody fragments possessing all antigen-binding sites. Generally, Fv antibodies also contain a polypeptide linker between the VH and VL domains and are capable of forming the structure required for antigen binding. The antigen-binding domain is typically an scFv (single-chain variable fragment). The size of an scFv is generally 1 / 6 that of a complete antibody. Single-chain antibodies are preferably single-amino acid sequences encoded by a single nucleotide chain. As a preferred embodiment of the invention, the scFv is a single-chain antibody that specifically recognizes GPC3, BCMA, or CD19.

[0188] For the hinge region and transmembrane region (transmembrane domain), the CAR can be designed to include a transmembrane domain fused to the extracellular domain of the CAR. In one implementation, a transmembrane domain naturally associated with one of the domains in the CAR is used. In some examples, the transmembrane domain can be selected, or modified by amino acid substitution, to avoid binding such a domain to the transmembrane domain of the same or different surface membrane proteins, thereby minimizing interactions with other members of the receptor complex.

[0189] The intracellular domains in the CAR of this invention include the 4-1BB signal transduction domain and the CD3ζ signal transduction domain.

[0190] The CAR-T cells of the present invention can be derived from the patient's own T cells or from allogeneic T cells. The method for preparing CAR-T cells from allogeneic T cells of the present invention is briefly described below.

[0191] Universal allogeneic CAR-T (UCAR-T)

[0192] In traditional CAR-T cell therapy, the patient's own T cells (or those from a heterologous donor) are first isolated, activated, and genetically modified to produce CAR-T cells, which are then injected into the same patient. This method results in an extremely low probability of graft-versus-host disease, as the antigens are recognized by the T cells in a non-MHC-restricted manner. However, this treatment method is heavily dependent on the individual patient's condition, and the time and financial costs associated with isolating and modifying the cells are very high. Therefore, there is a need in this field to develop universal CAR-T cells that can be readily available to any patient, abbreviated as UCAR-T cells.

[0193] In addition to the traditional autologous CAR-T preparation method, the preparation of UCAR-T cells also requires the knockout or silencing of genes related to immune rejection in T cells. These genes include, but are not limited to, CD3, CD95, and HLA.

[0194] Human leukocyte antigens (HLA), also known as histocompatibility complexes, are the main markers used by the body's immune system to distinguish "self" from "non-self." HLA can be divided into three major classes: I, II, and III. HLA-I molecules are expressed on the cell membrane surface of almost all nucleated cells, while HLA-II molecules are mainly expressed on the surface of antigen-presenting cells such as dendritic cells, macrophages, and B cells. Based on different gene loci, HLA-I molecules can be further divided into six subclasses: HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, and HLA-G. Among them, HLA-A, HLA-B, and HLA-C belong to the major histocompatibility complex (highly polymorphic), while HLA-E, HLA-F, and HLA-G belong to the minor histocompatibility complex (relatively conserved sequences).

[0195] All HLA-I molecules are heterodimers composed of a highly polymorphic α chain and a constant β chain, also known as β-microglobulin (B2M). After binding to antigenic peptides inside the cell, both the α and β chains of HLA-I are transported to the cell membrane surface. Both the α and β chains of HLA-I are indispensable; otherwise, the assembly of HLA molecules with antigenic peptides and their expression on the cell membrane surface will be affected. Therefore, knocking out the B2M gene can inactivate HLA-I molecules.

[0196] CIITA (MHC class II transactivator) is a core transcriptional regulator that controls the expression of HLA class II molecules. It activates the transcription of HLA class II genes by coordinating multiple transcription factors and the chromatin remodeling complex, thereby controlling the expression level of HLA class II molecules. Knocking out the CIITA gene inactivates HLA class II molecules.

[0197] If both HLA-I and HLA-II are knocked out, NK cells will unnecessarily kill CAR-T cells. To avoid this, this invention provides two strategies:

[0198] (1) In UCAR-T, knock out HLA-A and HLA-B in HLA-I, but retain HLA-C, and knock out HLA-II (CIITA); or

[0199] (2) Knock out HLA-I (B2M) and HLA-II (CIITA) in UCAR-T and express exogenous HLA-E;

[0200] Both of these strategies can reduce the killing effect of NK cells on UCAR-T cells.

[0201] In addition to knocking out HLA molecules, the UCAR-T of this invention also knocks out or silences the TRAC and CD95 genes to further reduce immune rejection and enhance the tumor-suppressing ability of UCAR-T.

[0202] Currently, commonly used gene knockout or silencing methods include CRISPR / Cas9, TALENs (transcription activator-like (TAL) effector nucleases), and ZFNs (Zinc finger nucleases). CRISPR / Cas9 will be used as an example to illustrate the gene knockout method of this invention.

[0203] The CRISPR / Cas9 system consists of two parts: the Cas9 protein and sgRNA. Its mechanism of action involves the sgRNA forming a Cas9-sgRNA complex with the Cas9 protein via its Cas9 handle. The complementary base pairing region of the sgRNA in the Cas9-sgRNA complex pairs with the target sequence of the target gene according to the base pairing principle. Cas9 then uses its endonuclease activity to cleave the target DNA sequence. Compared to traditional genome editing technologies, the CRISPR / Cas9 system has several significant advantages: ease of use, simplicity, low cost, programmability, and the ability to edit multiple genes simultaneously.

[0204] In a preferred embodiment, multiple genes in T cells are simultaneously knocked out using sgRNAs that target multiple genes to be knocked out. The sequence of the sgRNA is as follows:

[0205] TRAC:TCAGGGTTCTGGATATCTGT(SEQ ID NO:7);

[0206] HLA-A: GGACCTGCGCTCTTGGACCG (SEQ ID NO: 8);

[0207] HLA-B:GCTGTCGAACCTCACGAACT(SEQ ID NO:9);

[0208] HLA-II(CIITA):TCAACTGCGACCAGTTCAGC(SEQ ID NO:10);

[0209] HLA-I (B2M): CGCGAGCACAGCTAAGGCCA (SEQ ID NO: 11);

[0210] CD95: GAGGGTCCAGATGCCCAGCA (SEQ ID NO: 12).

[0211] In a preferred embodiment, in the UCAR-T of the present invention, TRAC, HLA-I (B2M), HLA-II (CIITA), and CD95 are knocked out; or the TRAC, HLA-A, HLA-B, HLA-II (CIITA), and CD95 genes are knocked out.

[0212] This invention provides a one-step method for preparing UCAR-T cells. By using non-viral (plasmid) electroporation, a mixture of a vector expressing proteins such as CAR and a knockout gene sgRNA-Cas9 can be delivered into T cells in one step, simultaneously achieving gene knock-in and knockout.

[0213] Pharmaceutical Composition

[0214] The present invention also provides a composition. In a preferred embodiment, the composition is a pharmaceutical composition comprising the above-described CAR-T cells or universal UCAR-T cells co-expressing an anti-PD-1 antibody, and a pharmaceutically acceptable carrier. Typically, these substances are formulated in a non-toxic, inert, and pharmaceutically acceptable aqueous carrier medium, wherein the pH is typically about 5-8, preferably about 6-8, although the pH may vary depending on the nature of the formulated substances and the condition to be treated. The formulated pharmaceutical composition can be administered via conventional routes, including (but not limited to): intratumoral, intraperitoneal, intravenous, or local administration.

[0215] The pharmaceutical compositions of the present invention contain a safe and effective amount (e.g., 0.001-99 wt%, preferably 0.01-90 wt%, more preferably 0.1-80 wt%) of the above-described CAR-T cells co-expressing anti-PD-1 antibodies of the present invention or universal UCAR-T cells, and a pharmaceutically acceptable carrier or excipient. Such carriers include (but are not limited to): saline, buffer, glucose, water, glycerol, ethanol, and combinations thereof. The pharmaceutical formulation should be matched to the route of administration. The pharmaceutical compositions of the present invention can be formulated into injectable forms, for example, prepared by conventional methods using physiological saline or an aqueous solution containing glucose and other excipients. Pharmaceutical compositions such as injections and solutions are preferably manufactured under sterile conditions. The dosage of the active ingredient is a therapeutically effective amount, for example, about 1 microgram / kg body weight to about 5 milligrams / kg body weight per day. Furthermore, the CAR-T cells of the present invention can also be used with other therapeutic agents.

[0216] When using a pharmaceutical composition, a safe and effective amount of the immunoconjugate is administered to mammals. This safe and effective amount is typically at least about 10 micrograms per kilogram of body weight, and in most cases does not exceed about 50 milligrams per kilogram of body weight. Preferably, the dose is about 10 micrograms per kilogram of body weight to about 20 milligrams per kilogram of body weight. Of course, the specific dosage should also take into account factors such as the route of administration and the patient's health condition, which are all within the scope of a skilled physician's expertise.

[0217] application

[0218] The present invention provides a method for treating tumors, comprising administering a therapeutically effective amount of the present invention's CAR-T cells or UCAR-T cells to a subject in need of such treatment.

[0219] The CAR-modified T cells of the present invention can be administered alone or as a pharmaceutical composition in combination with a diluent and / or other components such as IL-2, IL-17, or other cytokines or cell populations. In short, the pharmaceutical compositions of the present invention may comprise target cell populations as described herein, combined with one or more pharmaceutically or physiologically acceptable carriers, diluents, or excipients. Such compositions may comprise buffers such as neutral buffered saline, sulfate buffered saline, etc.; carbohydrates such as glucose, mannose, sucrose, or dextran, mannitol; proteins; peptides or amino acids such as glycine; antioxidants; chelating agents such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide); and preservatives. The compositions of the present invention are preferably formulated for intravenous administration.

[0220] The pharmaceutical compositions of the present invention can be administered in a manner suitable for the disease to be treated (or prevented). The amount and frequency of administration will be determined by factors such as the patient's condition, and the type and severity of the patient's disease—although the appropriate dosage can be determined by clinical trials.

[0221] When referring to "immunologically effective amount," "antitumor effective amount," "tumor-suppressive effective amount," or "therapeutic amount," the precise amount of the composition of the invention to be administered can be determined by a physician, taking into account individual differences in the patient's (subject's) age, weight, tumor size, degree of infection or metastasis, and disease condition. It can generally be indicated that a pharmaceutical composition including T cells described herein can be administered in doses of 10... 4 Up to 10 9 A dose of cells / kg body weight, preferably 10. 5 Up to 10 6The T-cell composition can be administered at a dose of cells per kg of body weight (including all integer values ​​within those ranges). These doses can also be administered multiple times. The cells can be administered using infusion techniques known in immunotherapy (see, for example, Rosenberg et al., New Eng. J. of Med. 319:1676, 1988). The optimal dose and treatment regimen for a specific patient can be readily determined by a physician skilled in the medical field by monitoring the patient's disease signs and thus adjusting the treatment accordingly.

[0222] The application of the target composition can be performed in any convenient manner, including by spraying, injection, swallowing, infusion, implantation, or transplantation. The compositions described herein can be administered to patients subcutaneously, intradermally, intratumorally, intranodally, intraspinally, intramuscularly, intravenously (iv), or intraperitoneally. In one embodiment, the T-cell composition of the present invention is administered to a patient by intradermal or subcutaneous injection. In another embodiment, the T-cell composition of the present invention is preferably administered by intravenous injection. The T-cell composition can be injected directly into the tumor, lymph node, or site of infection.

[0223] In some embodiments of the invention, activated and expanded cells, using the methods described herein or other methods known in the art for expanding T cells to a therapeutic level, are administered to a patient in combination with any number of relevant therapeutic modalities (e.g., before, during, or after). In further embodiments, the T cells of the invention can be used in combination with chemotherapy, radiation, immunosuppressants such as cyclosporine, azathioprine, methotrexate, mycophenolate mofetil, and FK506, antibodies, or other immunotherapeutic agents.

[0224] The dosage of the above treatments administered to patients will vary depending on the precise nature of the condition being treated and the recipient of the treatment. The dosage ratios administered to individuals can be implemented according to accepted practices in the field. Typically, 1 × 10⁻⁶ ppm can be administered per treatment or per course of treatment. 6 One to 1×10 10 The modified T cells of this invention are administered to a patient, for example, via intravenous infusion.

[0225] The advantages of this invention are:

[0226] (1) The CAR-T cells of the present invention co-express anti-PD-1 antibody, which on the one hand can be used in combination with PD-1 to treat tumors, and on the other hand can reduce CAR-T depletion only in the local area where CAR-T exists, thereby reducing the possible toxic reactions when anti-PD-1 antibody is injected into the whole body;

[0227] (2) The CAR-T cells of the present invention co-express PD-1VHH antibody. The nanobody has advantages such as small molecular weight and good permeability, which can significantly reduce the volume of the delivery carrier.

[0228] (3) The present invention also provides allogeneic universal UCAR-T cells, which reduce the host’s rejection response to allogeneic cells and also reduce the killing rate of NK cells to UCAR-T by partially knocking out HLA-I molecules or expressing exogenous HLA-E molecules.

[0229] (4) The present invention prepares UCAR-T cells by non-viral (plasmid) electroporation, which can achieve the knock-in of exogenous genes (such as CAR, anti-PD-1 antibody encoding genes) and the knock-out of immune rejection-related genes (such as HLA, CD95 genes) in one electroporation.

[0230] The present invention will be further illustrated below with reference to specific embodiments. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of the invention. Experimental methods in the following embodiments, unless otherwise specified, are generally performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or as recommended by the manufacturer. Unless otherwise stated, percentages and fractions are weight percentages and weight fractions.

[0231] Example 1: PD-1VHH antibody and humanization

[0232] (I) Antibody sequence

[0233] Camels were immunized with recombinant PD-1 protein antigen. After library construction and screening, a VHH antibody with high affinity for PD-1 protein was obtained. In this invention, it is referred to as the PD1 VHH parent strain, and its sequence is as follows:

[0234] PD1 VHH parent full length (SEQ ID NO:4):

[0235] QVKLVESGGGSVQAGGSLRLSCARANFASSPKTMAWFRQAPGKEREGVASIYTTTGITYYTDSVQGRFSISQDMAKNTVYLQMNSLKPEDTAMYYCAAALTEIGRYRLYARQYDFWGQGTQVTVSS

[0236] The CDR sequence of the PD1 VHH mother determined using the Kabat method is as follows:

[0237] CDR1: PCTMA (SEQ ID NO:1)

[0238] CDR2:SIYTTTGITYYTDSVQG(SEQ ID NO:2)

[0239] CDR3: ALTEIGRYRLYARQYDF (SEQ ID NO: 3).

[0240] Humanization of the PD1 VHH parent strain yielded two humanized PD1 VHH strains, named PD1-18 and PD1-25, with the following sequences:

[0241] PD1-18 (SEQ ID NO:5):

[0242] QVQLVESGGGLVQPGGSLRLSCARANFASSPKTMAWFRQAPGKGLEWVSSIYTTTGITYYADSVKGRFTISRDNAKNTLYLQMNSLKAEDTAVYYCAAALTEIGRYRLYARQYDFWGQGTLVTVSS

[0243] PD1-25 (SEQ ID NO:6):

[0244] QVQLVESGGGLVOPGGSLRLSCARANFASSPKTMAWFRQAPGKEREWVSSIYTTTGITYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAAALTEIGRYRLYARQYDFWGQGTLVTVSS

[0245] PD1-18 and PD1-25 have the following CDR combinations (determined based on the Kabat method):

[0246] CDR1: PCTMA (SEQ ID NO:1)

[0247] CDR2:SIYTTTGITYYADSVKG(SEQ ID NO:34)

[0248] CDR3: ALTEIGRYRLYARQYDF (SEQ ID NO: 3).

[0249] (ii) Antibody affinity

[0250] The binding of the parent cell and two humanized nanobodies to PD-1-overexpressing 293F cells (293F-PD1) was detected by FACS. The results are shown in Table 1.

[0251] Table 1

[0252]

[0253]

[0254] (III) Blocking activity of nanobodies against PD-1 / PD-L1

[0255] Using PD-L1-overexpressing 293F cells, the binding of PD-1 to cells was detected (using FACS assay) under conditions of PD-1 alone or PD-1 + nanobody. The results are shown in Table 2.

[0256] Table 2

[0257]

[0258]

[0259] The results showed that the PD1 VHH parent and the two humanized VHHs of the present invention have high affinity for PD-1 and have blocking activity against PD-1 / PD-L1.

[0260] In the following examples, CAR-T cells co-expressing anti-PD-1 antibody were constructed using the PD1 VHH parent cell and two humanized VHH cells. The PD-1 single-chain antibody sequence in US Patent US10512689B2 was used as a control, abbreviated as PD1-scFv, and the sequence is shown in SEQ ID NO:14: EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIKGGGGSGGGGSGGGGSQVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSS (SEQ ID NO:14).

[0261] Example 2: Plasmid construction and CAR-T preparation

[0262] (I) Plasmid Construction

[0263] First, molecular constructs were constructed for the one-time insertion of CAR, anti-PD-1 antibody and other exogenous proteins at the TRAC site. All molecular constructs contained homologous arms of the TRAC site, with each homologous arm being 400 bp in length. The constructs could contain artificially introduced EF1A promoter or HPGK promoter, or they could not contain artificially introduced promoters, i.e., they could use endogenous promoters.

[0264] The components of each molecular construct are described below: XX CAR represents a CAR targeting XX, possessing a scFv or VHH targeting XX and a hinge-transmembrane-intracellular region; P2A, F2A, T2A, and E2A represent self-cleaving 2A peptides, located between different exogenous proteins, used to separate different proteins; IL15 and IL21 represent cytokines, PD1 represents an anti-PD-1 antibody, with the antibody type (VHH or scFv) and sequence indicated in parentheses; TIGIT scFv represents a single-chain antibody sequence targeting TIGIT; dnTGFbRII represents a dominant mutant TGFb receptor II protein; HLA-E SCT represents an HLA-E single-chain trimer; SA is a splicing acceptor.

[0265] The naming of each molecular construct and the connection method of the components are shown below:

[0266] CG-102-12:

[0267] Left homologous arm - GPC3 CAR - P2A - IL15 - F2A - IL21 - POLYA - Right homologous arm

[0268] CG-102-12E:

[0269] Left homologous arm - EF1A promoter - GPC3 CAR - P2A - IL15 - F2A - IL21 - T2A - PD1 (control PD1-scFv, SEQ ID NO:14) - POLYA - Right homologous arm

[0270] CG-102-12E1:

[0271] Left homologous arm - EF1A promoter - GPC3 CAR - P2A - IL15 - F2A - IL21 - T2A - PD1 (VHH parent, SEQ ID NO: 4) - POLYA - Right homologous arm

[0272] CG-102-12A:

[0273] Left homologous arm - EF1A promoter - GPC3 CAR - P2A - PD1 (VHH parent, SEQ ID NO:4) - IL15 - E2A - IL21 - POLYA - Right homologous arm

[0274] CG-102-12D:

[0275] Left homologous arm - HPGK promoter - GPC3 CAR - P2A - IL15 - F2A - IL21 - POLYA - Right homologous arm CG - 102 - 12D1:

[0276] Left homologous arm - EF1A promoter - GPC3 CAR - P2A - IL21 - F2A - IL15 - POLYA - Right homologous arm

[0277] CG-101-3-5-55:

[0278] Left homologous arm - EF1A promoter - CD19 CAR - P2A - PD1 (VHH parent, SEQ ID NO:4) - F2A - IL15 - E2A - IL21 - POLYA - Right homologous arm

[0279] CG-102-12B3:

[0280] Left homologous arm - EF1A promoter - SA - GPC3 CAR - E2A - PD1 (VHH parent, SEQ ID NO:4) - P2A - IL21 - F2A - IL15 - POLYA - Right homologous arm

[0281] CG-105-12TB5:

[0282] Left homologous arm - EF1A promoter - BCMACAR-P2A-dnTGFbRII-T2A-PD1 (humanized VHH PD1-25, SEQ ID NO:6) - F2A-IL15-E2A-IL21-POLYA - Right homologous arm

[0283] CG-105-12EB:

[0284] Left homologous arm - EF1A promoter - BCMACAR - P2A - HLA - ESCT - F2A - IL15 - E2A - IL21 - POLYA - Right homologous arm

[0285] CG-105-12EB25:

[0286] Left homologous arm - EF1A promoter - BCMACAR-P2A-HLA-E SCT-T2A-PD1 (humanized VHH PD1-25, SEQ ID NO:6) - F2A-IL15-E2A-IL21-POLYA - Right homologous arm

[0287] CG-102-12C18B:

[0288] Left homologous arm - EF1A promoter - GPC3 CAR-T2A-PD1 (humanized VHH PD1-18, SEQ ID NO:5) - P2A-TIGIT scFv-F2A-IL21-E2A-IL15-POLYA-right homologous arm

[0289] The sequence of each component is shown in Table 3:

[0290] Table 3 shows the nucleotide or amino acid sequences of the elements.

[0291]

[0292]

[0293]

[0294] The coding DNA sequences of the above molecular constructs were inserted into plasmid vectors by molecular cloning to obtain multiple plasmids. The naming convention of the plasmids followed that of the molecular constructs. For example, the plasmid expressing the CG-102-12 molecular construct was called the CG-102-12 plasmid.

[0295] (II) Preparation of CAR-T cells via non-viral electroporation

[0296] Conventional CAR-T cells are typically prepared using viral transfection. In this invention, a non-viral method is used to prepare CAR-T cells, specifically by directly electroporating the constructed plasmid into T cells. The specific method is as follows:

[0297] First, a complex was formed by mixing sgRNA targeting the TRAC site and Cas9 protein. After T cells were activated by Dynabead for 48-72 hours, the sgRNA-Cas9 complex was mixed with the activated T cells and plasmids, and then electroporated. The sgRNA targeting the TRAC site was: TCAGGGTTCTGGATATCTGT (SEQ ID NO:7).

[0298] Example 3: Effects of PD-1 knockout or co-expression of anti-PD-1 antibody on CAR-T activation levels

[0299] (I) The effect of PD-1 knockout on cell activation and expansion in CAR-T cells prepared by non-viral electroporation

[0300] Previous reports have shown that knocking out PD-1 in CAR-T cells prepared using conventional viral transfection can enhance CAR-T cell activation and proliferation capacity. In this example, we verified whether knocking out PD-1 had the same effect on CAR-T cells prepared by electroporation using non-viral plasmids. The method is as follows:

[0301] The plasmid electroporation method was the same as in Example 1. T cells were electroporated with the CG-102-12 plasmid to obtain CG-102-12 cells; the CG-102-12 plasmid, the sgRNA (SEQ ID NO:7)-Cas9 complex targeting the TRAC site, and the sgRNA (GGCCAGGATGGTTCTTAGGT, SEQ ID NO:13)-Cas9 complex targeting PD-1 were mixed and electroporated into T cells to obtain PD-1 knockout CG-102-12 CAR-T cells, named CG-102-12-PD1 cells.

[0302] Similarly, T cells were electroporated with the CG-102-12D plasmid to obtain CG-102-12D cells; the CG-102-12D plasmid, the sgRNA (SEQ ID NO:7)-Cas9 complex targeting the TRAC site, and the sgRNA (SEQ ID NO:13)-Cas9 complex targeting PD-1 were mixed and electroporated into T cells to obtain PD-1 knockout CG-102-12D cells, which were named CG-102-12D-PD1 cells.

[0303] The four types of CAR-T cells prepared and cryopreserved above—CG-102-12, CG-102-12-PD1, CG-102-12D, and CG-102-12D-PD1—were thawed and then added to target cells Huh-7 (human liver cancer cells) at an effector-to-target ratio of E:T = 1:1. The changes in the total number of CAR-T cells were recorded to assess the activation level of CAR-T cells.

[0304] The results are as follows Figure 1 As shown, the activation levels of CG-102-12 (without PD-1 knockout) and CG-102-12-PD1 (PD-1 knockout) were similar, as were the activation levels of CG-102-12D (without PD-1 knockout) and CG-102-12D-PD1 (PD-1 knockout). This indicates that for CAR-T cells prepared using non-viral methods, whether or not PD-1 is knocked out has no significant effect on cell activation and expansion, which differs from CAR-T cells prepared using viral methods.

[0305] (II) The effect of co-expression of anti-PD-1 antibody on cell activation and expansion in CAR-T cells prepared by non-viral electroporation.

[0306] Since knocking out the PD-1 protein in CAR-T cells prepared using non-viral methods cannot promote T cell activation and proliferation, this experiment investigated whether co-expression of anti-PD-1 antibodies could activate CAR-T cells prepared using non-viral methods. The method is as follows:

[0307] T cells were electroporated with the CG-102-12D1 plasmid to obtain CG-102-12D1 cells, which do not express anti-PD-1 antibody;

[0308] T cells were electroporated with CG-102-12A plasmid to obtain CG-102-12A cells, which co-expressed anti-PD-1 antibody.

[0309] The two types of CAR-T cells, CG-102-12A and CG-102-12D1, prepared and cryopreserved as described above, were thawed and then added to target cells Huh-7 at an effector-to-target ratio of E:T = 1:30. The changes in the total number of CAR-T cells were recorded to assess the activation level of CAR-T cells.

[0310] The results are as follows Figure 2 As shown, the amplification level of CG-102-12A cells co-expressing anti-PD-1 antibody was significantly better than that of CG-102-12D1 cells not expressing anti-PD-1 antibody. This indicates that for CAR-T cells prepared by non-viral methods, co-expression of anti-PD-1 antibody can improve the activation and amplification levels of CAR-T cells.

[0311] Example 4: In vivo tumor-suppressive activity of CAR-T cells co-expressing anti-PD-1 antibody

[0312] To verify the tumor-suppressive activity of CAR-T cells co-expressing anti-PD-1 antibodies in vivo, CAR-T cells expressing different types (VHH or scFv) of anti-PD-1 antibodies and control cells not expressing anti-PD-1 antibodies were constructed, as detailed below:

[0313] The plasmid electroporation method was the same as in Example 1. T cells were electroporated with the CG-102-12 plasmid to obtain CG-102-12 cells, which served as control cells not expressing anti-PD-1 antibody; T cells were electroporated with the CG-102-12E plasmid to obtain CG-102-12E cells, which expressed anti-PD-1 scFv (SEQ ID NO:14); T cells were electroporated with the CG-102-12E1 plasmid to obtain CG-102-12E1 cells, which expressed anti-PD-1 VHH.

[0314] Human hepatocellular carcinoma line HepG2 was inoculated into immunodeficient mice (NCG) to prepare NCG HepG2 subcutaneous tumor mice. The three types of CAR-T cells (1E6 / mouse) were intravenously injected into the NCG HepG2 subcutaneous tumor mice, and the mouse body weight and subcutaneous tumor volume were measured periodically.

[0315] The results are as follows Figure 3As shown, CG-102-12E and CG-102-12E1 cells co-expressing anti-PD-1 antibody showed better tumor suppression ability than control cells CG-102-12, and had no significant effect on mouse body weight; CG-102-12E1 cells expressing VHH antibody showed even better tumor suppression effect than CG-102-12E cells expressing scFv.

[0316] Example 5: One-step preparation of universal UCAR-T

[0317] For the preparation of universal UCAR-T cells from allogeneic sources, in addition to expressing exogenous CAR proteins, it is also necessary to knock out some genes in T cells. Conventional viral transfection methods for preparing UCAR-T cells generally require two steps: gene knockout and gene introduction. In this embodiment, a non-viral plasmid electroporation method is used. The sgRNA-Cas9 complex of the knockout gene and the plasmid of the introduction gene are mixed and transfected into T cells together, achieving both knockout and gene introduction in a single step. Therefore, UCAR-T cells can be prepared in a single operation. The following types of UCAR-T cells were prepared using this one-step method:

[0318] (I) Gene knockout strategy for universal UCAR-T

[0319] First, knockout of HLA-I and HLA-II molecules can reduce the rejection response to allogeneic CAR-T cells, but may lead to unnecessary NK cell killing of CAR-T cells. To reduce NK cell killing of CAR-T cells, the following two strategies are employed:

[0320] Strategy 1: Knock out HLA-A and HLA-B in HLA-I while retaining HLA-C, and knock out HLA-II and CD95. For example, CAR-T cells that have been introduced with the CG-102-12C18B plasmid and have had HLA-A, HLA-B, HLA-II, and CD95 knocked out are named CG-102-12C18B-ABII95 cells; similarly, replacing the CG-102-12C18B plasmid with the CG-105-12TB5 plasmid and the CG-101-5-55 plasmid, respectively, results in cells named CG-105-12TB5-ABII95 and CG-101-5-55-ABII95 cells, respectively.

[0321] Strategy 2: Knock out HLA-I, HLA-II, and CD95, and express HLA-E (single-chain trimeric form, HLA-ESCT) in cells. For example, CAR-T cells that are introduced with the CG-105-12EB plasmid (containing HLA-E SCT) and have HLA-I, HLA-II, and CD95 knocked out are named CG-105-12EB-I / II / 95 cells.

[0322] Control 1: CAR-T cells infused with CG-105-12 plasmid and with simultaneous knockout of HLA-I and HLA-II were named CG-105-12-I / II cells. These cells had complete knockout of HLA-1 and served as a control for partial knockout of HLA-I.

[0323] Control 2: CAR-T cells infused with CG-105-12EB plasmid (containing HLA-E SCT) and with simultaneous knockout of HLA-I and HLA-II were named CG-105-12EB-I / II cells. These cells did not have CD95 knocked out and served as a control.

[0324] (II) Preparation of UCAR-T cells by non-viral electroporation method

[0325] After T cells were activated by Dynabead for 48-72 hours, they were mixed with sgRNA, Cas9, and plasmids encoding various CARs and additional molecules, and then electroporated. Cell growth characteristics were recorded at specified time points during the preparation process.

[0326] The sequence of the sgRNA used to knock out the gene is shown below:

[0327] HLA-A: GGACCTGCGCTCTTGGACCG (SEQ ID NO: 8);

[0328] HLA-B:GCTGTCGAACCTCACGAACT(SEQ ID NO:9);

[0329] HLA-II(CIITA):TCAACTGCGACCAGTTCAGC(SEQ ID NO:10);

[0330] HLA-I (B2M): CGCGAGCACAGCTAAGGCCA (SEQ ID NO: 11);

[0331] CD95: GAGGGTCCAGATGCCCAGCA (SEQ ID NO: 12).

[0332] The viability, CAR expression rate, and total number of the three types of UCAR-T cells and two types of autologous CAR-T cells prepared are as follows: Figure 4 As shown in the figure. The results showed that both gene-knockout UCAR-T cells and autologous CAR-T cells were successfully prepared, and had high viability and expansion rates.

[0333] Example 6: NK cell killing of UCAR-T cells

[0334] In this embodiment, the killing level of NK cells on the five types of UCAR-T cells prepared in Example 5 was detected. The five types of UCAR-T cells were: CG-102-12C18B-ABII95, CG-105-12TB5-ABII95, CG-101-5-55-ABII95, CG-105-12EB-I / II / 95, CG-105-12-I / II, and CG-105-12EB-I / II cells.

[0335] PBMCs were treated with Miltenyi magnetic beads to remove CD3-positive cells according to the manufacturer's kit instructions to obtain enriched NK cells. Calcium-AM-labeled UCAR-T cells were mixed with NK cells for 1 day, and the number of viable cells was detected by flow cytometry (fluorescence indicates positive cells).

[0336] The results are as follows Figure 5 As shown, cells with complete HLA-I knockout (CG-105-12-I / II) are sensitive to NK cells, with an NK cell killing rate as high as 90%. Cells with only HLA-A, HLA-B, and HLA-II knockouts (CG-102-12C18B-ABII95, CG-105-12TB5-ABII95, CG-101-5-55-ABII95) and cells with HLA-I / II knockout expressing HLA-E (CG-105-12EB-I / II / 95) all showed reduced sensitivity to NK cells. This indicates that the knockout strategy of the present invention can effectively reduce NK cell killing of UCAR-T cells.

[0337] Example 7: In vivo tumor-suppressing effect of CAR-T cells co-expressing the PD-1VHH parent gene.

[0338] In this embodiment, the tumor-suppressing effects of CG-101-3-55-ABII95UCAR-T or CG-102-12B3 CAR-T co-expressing PD-1VHH (parent) in mice were verified.

[0339] Specifically as follows:

[0340] (I) Animal efficacy of CG-101-3-55-ABII95

[0341] 5E5 Raji cells were inoculated into NCG-deficient mice, resulting in NCG Raji mice after 3 days. CG-101-3-55-ABII95 (5E6 / mouse) was injected intravenously into NCG Raji mice (3 mice / group). Mouse body weight was measured twice weekly, and tumor growth was measured weekly using fluorescence detection.

[0342] The results are as follows Figure 6As shown, during the observation period, all mice in the control group died on day 17, while the mice in the CG-101-3-55-ABII95 treatment group had a 100% survival rate and no tumor growth. This demonstrates that the UCAR-T cells of the present invention have excellent in vivo tumor-suppressing ability.

[0343] (II) Animal efficacy of CG-102-12B3

[0344] After subcutaneous inoculation of HepG2 cells into mice, the subcutaneous tumors were allowed to grow to approximately 100 mm. 3 At the age of 3, mice were intravenously injected with CG-102-12B3 CAR-T, with 3 mice per group. The weight and subcutaneous tumor volume of the mice were measured twice a week.

[0345] The results are as follows Figure 7 As shown, during the observation period, the tumors of mice injected with CG-102-12B3 did not grow, and the survival rate was 100%.

[0346] Example 8: Tumor-suppressive effect of UCAR-T co-expressing humanized PD-1VHH in mice

[0347] In this embodiment, the tumor-suppressing effect of the UCAR-T cell co-expressing humanized VHH PD1-25 of the present invention in mice was verified. Specifically:

[0348] Autologous CG-105-12TB5 CAR-T cells were prepared, and CD95 was knocked out to obtain CG-105-12TB5-95; HLA-A, HLA-B, HLA-II, and CD95 were knocked out to obtain CG-105-12TB5-ABII95. The killing effects of the three CAR-T cells on the NCG mouse RPMI-8226 subcutaneous tumor model were verified.

[0349] After subcutaneous inoculation of RPMI-8226 cells into mice, the subcutaneous tumors were observed to reach approximately 100 mm in size. 3 At the age of 3, the mice were intravenously injected with the three CAR-T cells (all expressing PD-1VHH), with 3 mice per group. The weight and subcutaneous tumor volume of the mice were measured twice a week.

[0350] The results are as follows Figure 8 As shown, during the observation period, tumors in mice injected with CG-105-12TB5, CG-105-12TB5-95, and CG-105-12TB5-ABII95 showed no growth, and the survival rate was 100%, with no significant difference among the three groups. This indicates that knocking out HLA-A, HLA-B, HLA-II, and CD95 has no effect on the killing ability of CAR-T cells, and that UCAR-T cells co-expressing humanized PD-1VHH (PD1-25) have excellent in vivo tumor-suppressing effects.

[0351] Example 9: Efficacy of UCAR-T co-expressing HLA-E SCT

[0352] As described in Example 5, CG-105-12EB-I / II / 95 cells with HLA-I, HLA-II, and CD95 knocked out and expressing HLA-E SCT were prepared.

[0353] (I) Phenotypic Detection

[0354] First, the activation and expansion levels of CG-105-12EB-I / II / 95 cells after stimulation with target cells H929 were detected, using the same experimental method as in Example 3. The results are as follows: Figure 9 As shown in Figure A, CG-105-12EB-I / II / 95 cells exhibit excellent expansion capabilities.

[0355] The phenotype of CG-105-12EB-I / II / 95 cells was examined before they were injected into mice, and the results are as follows: Figure 9 As shown in B.

[0356] After subcutaneous inoculation of RPMI-8226 cells into mice, the subcutaneous tumors were observed to reach approximately 100 mm in size. 3 At the time of injection, CG-105-12EB-I / II / 95 cells were injected intravenously in groups of three mice. Mouse body weight and subcutaneous tumor volume were measured twice weekly. After 34 days of intravenous injection, the phenotype of CAR-T cells in peripheral blood was examined, and the results are as follows: Figure 9 As shown in Figure C. The results showed that human cells accounted for over 90% of peripheral blood transplantation, and the expression rates of the knocked-out genes were all very low: HLA-I = 0.6%, HLA-II = 5%, HLA-E = 63%, and CD95 and CD3 = 0.1%.

[0357] (II) Comparison of in vivo efficacy of UCAR-T with and without CD95 knockout

[0358] First, CG-105-12EB-I / II cells with HLA-I and HLA-II knockouts, and CG-105-12EB-I / II / 95 cells with HLA-I, HLA-II, and CD95 knockouts were prepared. The killing effects of both on the NCG mouse RPMI-8226 subcutaneous tumor model were verified.

[0359] After subcutaneous inoculation of RPMI-8226 cells into mice, the subcutaneous tumors were observed to reach approximately 100 mm in size. 3 When the mice were small, they were injected intravenously with CG-105-12EB-I / II / 95 cells. Three mice were used per group, and the weight and subcutaneous tumor volume of the mice were measured twice a week.

[0360] The results are as follows Figure 10As shown, both types of UCAR-T cells exhibited excellent tumor-suppressing effects, with the CD95-knockout CG-105-12EB-I / II / 95 cells showing a more significant effect.

[0361] Example 10: Efficacy of CG-105-12EB25-I / II / 95

[0362] UCAR-TCG-105-12EB25-I / II / 95, co-expressing humanized VHH PD1-25 and HLA-E SCT, was prepared and subjected to phenotypic and in vivo efficacy tests.

[0363] After subcutaneous inoculation of RPMI-8226 cells into mice, the subcutaneous tumors were observed to reach approximately 100 mm in size. 3 When the mice were large, they were injected intravenously with CG-105-12EB25-I / II / 95, 3 mice per group, and the weight and subcutaneous tumor volume of the mice were measured twice a week.

[0364] The results are as follows Figure 11 As shown, the survival rate of mice was 100% during the observation period.

[0365] Phenotypic detection results are as follows Figure 12 As shown, the top figure represents the phenotype of CAR-T cells in animals before injection; the bottom figure represents the peripheral blood CAR-T phenotype 34 days after intravenous injection of CAR-T cells. The results showed that human cells accounted for over 90% of the peripheral blood transplantation, and the expression rates of the knocked-out genes were all very low: HLA-I = 0.6%, HLA-II = 5%, HLA-E = 63%, and CD95 and CD3 = 0.1%.

[0366] Example 11: Efficacy of CG-102-12C18B autologous and universal CAR-T

[0367] CG-102-12C18B and its universal version, which co-express humanized VHH PD1-18, were prepared, including CG-102-12C18B-95 with CD95 knockout and CG-102-12C18B-ABII95 with HLA-A, HLA-B, HLA-II and CD95 knockout.

[0368] After subcutaneous inoculation of HepG2-Luc cells into mice, the subcutaneous tumors were observed to reach approximately 100 mm in size. 3 At the time of birth, mice were intravenously injected with CG-102-12C18B, CG-102-12C18B-95, and CG-102-12C18B-ABII95, respectively, in groups of three. Body weight and subcutaneous tumor volume were measured twice weekly. Results are as follows: Figure 13 As shown, the survival rate of mice was 100% during the observation period.

[0369] Tumor fluorescence values ​​were measured 31 days after CAR-T injection. Results are as follows: Figure 14 As shown, the CG-102-12C18B-ABII95 treatment group had the best tumor-suppressing effect, and no tumor fluorescence was detected in mice.

[0370] All documents mentioned in this invention are incorporated herein by reference as if each document were individually incorporated by reference. Furthermore, it should be understood that after reading the foregoing teachings of this invention, those skilled in the art can make various alterations or modifications to this invention, and these equivalent forms also fall within the scope defined by the appended claims.

Claims

1. An engineered T cell, characterized in that, The engineered T cells express a chimeric antigen receptor (CAR) and secrete an anti-PD-1 antibody, the anti-PD-1 antibody having the following combination of complementarity-determining regions (CDRs): CDR1: PCTMA (SEQ ID NO:1) CDR2: SIYTTTGITYYTDSVQG(SEQ ID NO:2), or SIYTTTGITYYADSVKG(SEQ ID NO:34); CDR3: ALTEIGRYRLYARQYDF (SEQ ID NO: 3).

2. The engineered T cell of claim 1, wherein, The sequence of the anti-PD-1 antibody is selected from the following group: (a) A sequence as shown in any one of SEQ ID NO:4-6; or (b) A sequence that has at least 90% sequence identity with any of the sequences shown in SEQ ID NO:4-6.

3. The engineered T cell of claim 1, wherein, The engineered T cells further express exogenous proteins selected from the group consisting of cytokines, inhibitory signal blocking proteins, chimeric antigen receptors (CARs), or combinations thereof.

4. An allogeneic universal CAR-T cell, characterized in that, The TRAC gene and / or CD95 gene of the allogeneic universal CAR-T cells are knocked out or silenced, and the allogeneic universal CAR-T cells have characteristics selected from the group consisting of: (1) Knock out B2M and CIITA to express HLA-E; or (2) Knock out HLA-A, HLA-B and CIITA.

5. A polynucleotide comprising a nucleic acid sequence encoding a polypeptide of any one of claims 1-4. The polynucleotide contains a coding sequence for a secretory anti-PD-1 antibody, and the polynucleotide further contains coding sequences for one or more proteins selected from the group consisting of: (1) Chimeric antigen receptor CAR; (2) Cytokines; (3) Inhibitory signal blocking proteins; (4) HLA-E; The anti-PD-1 antibody has the following combination of complementarity-determining regions (CDRs): CDR1: PCTMA (SEQ ID NO:1) CDR2: SIYTTTGITYYTDSVQG(SEQ ID NO:2), or SIYTTTGITYYADSVKG(SEQ ID NO:34); CDR3: ALTEIGRYRLYARQYDF (SEQ ID NO: 3).

6. A vector, characterized in that, The carrier contains the polynucleotide as described in claim 5.

7. A pharmaceutical composition, characterized in that, The pharmaceutical composition contains: (1) An active ingredient selected from the group consisting of: engineered T cells as described in claim 1, or allogeneic universal CAR-T cells as described in claim 4; and (2) Pharmaceutically acceptable carrier.

8. A method for preparing engineered T cells as described in claim 1, characterized in that, The method includes the steps of: providing T cells to be modified, and introducing the polynucleotide as described in claim 5 or the vector as described in claim 6 into the T cells to obtain the engineered T cells.

9. A method for preparing allogeneic universal CAR-T cells as described in claim 4, characterized in that, The method includes providing T cells to be modified and performing the following operations on the T cells: (a) Knock out the immune rejection-related gene combination in the T cells; (b) Transfecting the exogenous vector expressing CAR into the T cells; The combination of immune rejection-related genes is as follows: (1) TRAC, B2M, CIITA, and CD95; or (2)TRAC, HLA-A, HLA-B, CIITA and CD95.

10. A kit for preparing CAR-T cells, characterized in that, The kit contains a container, and inside the container: (1) Knock-in reagent, wherein the knock-in reagent comprises an exogenous vector for expressing CAR; (2) Knockout reagents are used to knock out or silence combinations of immune rejection-related genes; The combination of immune rejection-related genes is as follows: (1) TRAC, B2M, CIITA, and CD95; or (2)TRAC, HLA-A, HLA-B, CIITA and CD95.

Citation Information

Patent Citations

  • Compositions comprising a combination of nivolumab and ipilimumab

    US10512689B2